Your browser doesn't support javascript.
loading
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.
Dibitetto, Diego; Liptay, Martin; Vivalda, Francesca; Dogan, Hülya; Gogola, Ewa; González Fernández, Martín; Duarte, Alexandra; Schmid, Jonas A; Decollogny, Morgane; Francica, Paola; Przetocka, Sara; Durant, Stephen T; Forment, Josep V; Klebic, Ismar; Siffert, Myriam; de Bruijn, Roebi; Kousholt, Arne N; Marti, Nicole A; Dettwiler, Martina; Sørensen, Claus S; Tille, Jean-Christophe; Undurraga, Manuela; Labidi-Galy, Intidhar; Lopes, Massimo; Sartori, Alessandro A; Jonkers, Jos; Rottenberg, Sven.
Affiliation
  • Dibitetto D; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. diego.dibitetto@marionegri.it.
  • Liptay M; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland. diego.dibitetto@marionegri.it.
  • Vivalda F; Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via Mario Negri 2, 20156, Milan, Italy. diego.dibitetto@marionegri.it.
  • Dogan H; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
  • Gogola E; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland.
  • González Fernández M; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland.
  • Duarte A; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
  • Schmid JA; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland.
  • Decollogny M; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.
  • Francica P; Oncode Institute, Amsterdam, The Netherlands.
  • Przetocka S; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
  • Durant ST; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland.
  • Forment JV; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.
  • Klebic I; Oncode Institute, Amsterdam, The Netherlands.
  • Siffert M; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland.
  • de Bruijn R; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
  • Kousholt AN; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland.
  • Marti NA; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
  • Dettwiler M; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland.
  • Sørensen CS; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland.
  • Tille JC; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, UK.
  • Undurraga M; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, UK.
  • Labidi-Galy I; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
  • Lopes M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.
  • Sartori AA; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.
  • Jonkers J; Oncode Institute, Amsterdam, The Netherlands.
  • Rottenberg S; Oncode Institute, Amsterdam, The Netherlands.
Nat Commun ; 15(1): 4430, 2024 May 24.
Article in En | MEDLINE | ID: mdl-38789420
ABSTRACT
Histone H2AX plays a key role in DNA damage signalling in the surrounding regions of DNA double-strand breaks (DSBs). In response to DNA damage, H2AX becomes phosphorylated on serine residue 139 (known as γH2AX), resulting in the recruitment of the DNA repair effectors 53BP1 and BRCA1. Here, by studying resistance to poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2-deficient mammary tumours, we identify a function for γH2AX in orchestrating drug-induced replication fork degradation. Mechanistically, γH2AX-driven replication fork degradation is elicited by suppressing CtIP-mediated fork protection. As a result, H2AX loss restores replication fork stability and increases chemoresistance in BRCA1/2-deficient tumour cells without restoring homology-directed DNA repair, as highlighted by the lack of DNA damage-induced RAD51 foci. Furthermore, in the attempt to discover acquired genetic vulnerabilities, we find that ATM but not ATR inhibition overcomes PARP inhibitor (PARPi) resistance in H2AX-deficient tumours by interfering with CtIP-mediated fork protection. In summary, our results demonstrate a role for H2AX in replication fork biology in BRCA-deficient tumours and establish a function of H2AX separable from its classical role in DNA damage signalling and DSB repair.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Histones / Drug Resistance, Neoplasm / BRCA1 Protein / BRCA2 Protein / DNA Replication / Poly(ADP-ribose) Polymerase Inhibitors Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2024 Type: Article Affiliation country: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Histones / Drug Resistance, Neoplasm / BRCA1 Protein / BRCA2 Protein / DNA Replication / Poly(ADP-ribose) Polymerase Inhibitors Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2024 Type: Article Affiliation country: Switzerland